Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-088087 · Präparat HOS-083615
Etravirine Concomitant use of etravirine with The concomitant administration of
nevirapine may cause a significant Viramune with NNRTIs is not
decrease in the plasma recommended (see section 4.4).
concentrations of etravirine and
loss of therapeutic effect of
etravirine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): etravirine (HOS-088088)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 085a174257b1599d7a522b55b3aed1620fedae0a9736a042681d19a0a32ea7c3 · Zeichen 5252–5632 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 34
HOS-088188 · Präparat HOS-083615
Etravirine Concomitant use of etravirine with The concomitant administration of
nevirapine may cause a significant Viramune with NNRTIs is not
decrease in the plasma recommended (see section 4.4).
concentrations of etravirine and
loss of therapeutic effect of
etravirine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): etravirine (HOS-088088)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 6c4c086dd0ebd11f3084f14b39824c898f3f04bf42ef9846039965963051432e · Zeichen 5410–5826 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 59
HOS-088281 · Präparat HOS-083615
Etravirine Concomitant use of etravirine with The concomitant administration of
nevirapine may cause a significant Viramune with NNRTIs is not
decrease in the plasma recommended (see section 4.4).
concentrations of etravirine and
loss of therapeutic effect of
etravirine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): etravirine (HOS-088088)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 085a174257b1599d7a522b55b3aed1620fedae0a9736a042681d19a0a32ea7c3 · Zeichen 5571–5951 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 11
HOS-108840 · Präparat HOS-093083
Abacavir, Zidovudine Abacavir, Zidovudine: The clinical significance of
Concentrations may be reduced reduced abacavir and zidovudine
due to increased glucuronidation concentrations is unknown.
by lopinavir/ritonavir.
Tenofovir disoproxil Tenofovir: No dose adjustment necessary.
fumarate (DF), 300 mg QD AUC: ↑ 32% Higher tenofovir concentrations
Cmax: ↔ could potentiate tenofovir
(equivalent to 245 mg Cmin: ↑ 51% associated adverse events,
tenofovir disoproxil) including renal disorders.
Lopinavir: ↔
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz, 600 mg QD Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 20% recommendation or consider
Cmax: ↓ 13% alternative therapy.
Cmin: ↓ 42%
Nevirapine, 200 mg BID Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 27% recommendation or consider
Cmax: ↓ 19% alternative therapy.
Cmin: ↓ 51%
Etravirine Etravirine: No dose adjustment necessary
AUC: ↓ 35%
(Lopinavir/ritonavir tablet Cmin: ↓ 45%
400/100 mg BID) Cmax: ↓ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) zidovudine (HOS-085837) efavirenz (HOS-087947) nevirapine (HOS-088064) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 7e8d3e75ebcfb46fcb48f151d995ceb0e62959fafd1f9cc35b54c2dafa32e31e · Zeichen 2252–4083 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 47–48
HOS-109002 · Präparat HOS-093083
47
Tenofovir disoproxil Tenofovir: No dose adjustment necessary.
fumarate (DF), 300 mg AUC: ↑ 32% Higher tenofovir concentrations could
QD Cmax: ↔ potentiate tenofovir associated
Cmin: ↑ 51% adverse events, including renal
(equivalent to 245 mg disorders.
tenofovir disoproxil) Lopinavir: ↔
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz, 600 mg QD Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 20% recommendation or consider
Cmax: ↓ 13% alternative therapy. Kaletra must not
Cmin: ↓ 42% be administered once daily in
combination with efavirenz.
Nevirapine, 200 mg Lopinavir: See section 4.2 for Kaletra dosage
BID AUC: ↓ 27% recommendation or consider
Cmax: ↓ 19% alternative therapy. Kaletra must not
Cmin: ↓ 51% be administered once daily in
combination with nevirapine.
Etravirine Etravirine: No dose adjustment necessary
AUC: ↓ 35%
(Lopinavir/ritonavir Cmin: ↓ 45%
tablet 400/100 mg BID) Cmax: ↓ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) efavirenz (HOS-087947) nevirapine (HOS-088064)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 1aa214ec519e800876deb03695523d141ba93dc4735974a07c93601e327b046a · Zeichen 2765–4474 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 83
HOS-109075 · Präparat HOS-093083
Abacavir, Zidovudine Abacavir, Zidovudine: The clinical significance of reduced
Concentrations may be reduced abacavir and zidovudine
due to increased glucuronidation concentrations is unknown.
by lopinavir/ritonavir.
Tenofovir disoproxil Tenofovir: No dose adjustment necessary.
fumarate (DF), 300 mg AUC: ↑ 32% Higher tenofovir concentrations
QD Cmax: ↔ could potentiate tenofovir
Cmin: ↑ 51% associated adverse events, including
(equivalent to 245 mg renal disorders.
tenofovir disoproxil) Lopinavir: ↔
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz, 600 mg QD Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 20% recommendation or consider
Cmax: ↓ 13% alternative therapy.
Cmin: ↓ 42% Kaletra must not be administered
once daily in combination with
efavirenz.
Nevirapine, 200 mg Lopinavir: See section 4.2 for Kaletra dosage
BID AUC: ↓ 27% recommendation or consider
Cmax: ↓ 19% alternative therapy.
Cmin: ↓ 51% Kaletra must not be administered
once daily in combination with
nevirapine.
Etravirine Etravirine: No dose adjustment necessary
AUC: ↓ 35%
(Lopinavir/ritonavir Cmin: ↓ 45%
tablet 400/100 mg BID) Cmax: ↓ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) zidovudine (HOS-085837) efavirenz (HOS-087947) nevirapine (HOS-088064) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c9296155c3ce5ef684722be8fb72dfceaf88100c0a3b2414e8bf3a028a9c0a3c · Zeichen 2392–4529 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-114813 · Präparat HOS-094169
10
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz 600 mg QD No clinically significant No dosage adjustment necessary.
interaction is observed.
Etravirine Etravirine Cmax ↓ 71% Co-administration of etravirine
Etravirine AUC ↓ 76% and Aptivus/ritonavir is not
Etravirine Cmin ↓ 82% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): etravirine (HOS-088088) efavirenz (HOS-087947) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 1f52c4759485e7bbf329fa25c2725f369aac4a1b6f9b19255f8f2e522e516692 · Zeichen 8556–9034 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-114814 · Präparat HOS-094169
Concomitant use of
Aptivus/ritonavir caused a
decrease of etravirine exposure
that could significantly impair
the virologic response to
etravirine.
Nevirapine The limited data available from a No dosage adjustment necessary.
No interaction study phase IIa study in HIV-infected
performed patients suggest that no
significant interaction is
expected between nevirapine and
TPV/r. Moreover a study with
TPV/r and another NNRTI
(efavirenz) did not show any
clinically relevant interaction
(see above).
Rilpivirine Concomitant use of rilpivirine Close monitoring for signs of
No interaction study with some ritonavir-boosted rilpivirine toxicity and possibly
performed protease inhibitors has also dose adjustment of rilpivirine
demonstrated an increase in the is recommended when co-
plasma concentrations of administered with
rilpivirine. Aptivus/ritonavir.
Protease inhibitors (PIs)
According to current treatment guidelines, dual therapy with protease inhibitors is generally not
recommended
Amprenavir/ritonavir Amprenavir Cmax ↓ 39% The concomitant use of Aptivus,
600/100 mg BID Amprenavir AUC ↓ 44% co-administered with low dose
Amprenavir Cmin ↓ 55% ritonavir, with
amprenavir/ritonavir is not
The clinical relevance of this recommended.
reduction in amprenavir If the combination is nevertheless
concentrations has not been considered necessary, a
established. monitoring of the plasma levels of
amprenavir is strongly
Mechanism unknown. encouraged (see section 4.4).
Atazanavir/ritonavir Atazanavir Cmax ↓ 57% The concomitant use of Aptivus,
300/100 mg QD Atazanavir AUC ↓ 68% co-administered with low dose
(TPV/r 500/100 mg BID) Atazanavir Cmin ↓ 81% ritonavir, with
atazanavir/ritonavir is not
Mechanism unknown. recommended.
If the co-administration is
Tipranavir Cmax 8% nevertheless considered
Tipranavir AUC 20% necessary, a close monitoring of
Tipranavir Cmin 75% the safety of tipranavir and a
monitoring of plasma
Inhibition of CYP 3A4 by concentrations of atazanavir are
atazanavir/ritonavir and strongly encouraged (see
induction by tipranavir/r. section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) protease (HOS-085623) etravirine (HOS-088088) amprenavir (HOS-086183) rilpivirine (HOS-088090) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 0f93136f565c07762f6fd595573f7b2523cf9549d537511b9eb823e270e5cf53 · Zeichen 9065–12757 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 10
HOS-116313 · Präparat HOS-094447
Medicinal products that affect darunavir exposure (cobicistat as pharmacoenhancer)
Darunavir and cobicistat are metabolised by CYP3A, and co-administration with CYP3A inducers
may therefore result in subtherapeutic plasma exposure to darunavir. Darunavir boosted with
cobicistat is more sensitive to CYP3A induction than ritonavir-boosted darunavir: co-administration of
darunavir/cobicistat with medicinal products that are strong inducers of CYP3A (e.g. St John’s Wort,
rifampicin, carbamazepine, phenobarbital, and phenytoin) is contraindicated (see section 4.3).
Co-administration of darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz,
etravirine, nevirapine, fluticasone, and bosentan) is not recommended (see interaction table below).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluticasone (HOS-108914) phenobarbital (HOS-085617) carbamazepine (HOS-085618) cobicistat (HOS-088111) etravirine (HOS-088088) efavirenz (HOS-087947) nevirapine (HOS-088064) bosentan (HOS-086291) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 499fe975cadb623876cff05939c4a88040eadfa5e659976989ecadcee7dec64a · Zeichen 1521–2284 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 13
HOS-116352 · Präparat HOS-094447
Co-administration with
PREZISTA co-administered with
cobicistat is not recommended (see
section 4.4).
Etravirine etravirine AUC ↓ 37% PREZISTA co-administered with
100 mg twice daily etravirine Cmin ↓ 49% low dose ritonavir and etravirine
etravirine Cmax ↓ 32% 200 mg twice daily can be used
darunavir AUC ↑ 15% without dose adjustments.
darunavir Cmin ↔
darunavir Cmax ↔ Co-administration with
PREZISTA co-administered with
cobicistat is not recommended (see
section 4.4).
Nevirapine nevirapine AUC ↑ 27% PREZISTA co-administered with
200 mg twice daily nevirapine Cmin ↑ 47% low dose ritonavir and nevirapine
nevirapine Cmax ↑ 18% can be used without dose
#
darunavir: concentrations were adjustments.
consistent with historical data
(↑ nevirapine from CYP3A inhibition) Co-administration with
PREZISTA co-administered with
cobicistat is not recommended (see
section 4.4).
Rilpivirine rilpivirine AUC ↑ 130% Boosted PREZISTA and rilpivirine
150 mg once daily rilpivirine Cmin ↑ 178% can be used without dose
rilpivirine Cmax ↑ 79% adjustments.
darunavir AUC ↔
darunavir Cmin ↓ 11%
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cobicistat (HOS-088111) etravirine (HOS-088088) rilpivirine (HOS-088090) nevirapine (HOS-088064) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e99fbb1bc5cf48c06c00d7bc510108ad103eae6c597f6e8b9fbcca6ec9073384 · Zeichen 15439–17813 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-116511 · Präparat HOS-094447
53
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine didanosine AUC ↓ 9% PREZISTA co-administered with
400 mg once daily didanosine Cmin ND low dose ritonavir and didanosine
didanosine Cmax ↓ 16% can be used without dose
darunavir AUC ↔ adjustments.
darunavir Cmin ↔ Didanosine is to be administered
darunavir Cmax ↔ on an empty stomach, thus it
should be administered 1 hour
before or 2 hours after
PREZISTA/ritonavir given with
food.
Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may
245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when PREZISTA
tenofovir Cmax ↑ 24% co-administered with low dose
#
darunavir AUC ↑ 21% ritonavir is given in combination
#
darunavir Cmin ↑ 24% with tenofovir disoproxil,
# particularly in patients with
darunavir Cmax ↑ 16%
underlying systemic or renal
(↑ tenofovir from effect on MDR-1
disease, or in patients taking
transport in the renal tubules)
nephrotoxic agents.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir
alafenamide is 200/10 mg once
daily when used with PREZISTA
with low dose ritonavir.
Abacavir Not studied. Based on the different PREZISTA co-administered with
Emtricitabine elimination pathways of the other NRTIs low dose ritonavir can be used
Lamivudine zidovudine, emtricitabine, stavudine, with these NRTIs without dose
Stavudine lamivudine, that are primarily renally adjustment.
Zidovudine excreted, and abacavir for which
metabolism is not mediated by CYP450,
no interactions are expected for these
medicinal compounds and PREZISTA
co-administered with low dose ritonavir.
Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)
Efavirenz efavirenz AUC ↑ 21% Clinical monitoring for central
600 mg once daily efavirenz Cmin ↑ 17% nervous system toxicity associated
efavirenz Cmax ↑ 15% with increased exposure to
#
darunavir AUC ↓ 13% efavirenz may be indicated when
#
darunavir Cmin ↓ 31% PREZISTA co-administered with
# low dose ritonavir is given in
darunavir Cmax ↓ 15%
combination with efavirenz.
(↑ efavirenz from CYP3A inhibition)
(↓ darunavir from CYP3A induction)
Efavirenz in combination with
PREZISTA/ritonavir 800/100 mg
once daily may result in
sub-optimal darunavir Cmin. If
efavirenz is to be used in
combination with
PREZISTA/ritonavir, the
PREZISTA/ritonavir 600/100 mg
twice daily regimen should be used
(see section 4.4).
Etravirine etravirine AUC ↓ 37% PREZISTA co-administered with
100 mg twice daily etravirine Cmin ↓ 49% low dose ritonavir and etravirine
etravirine Cmax ↓ 32% 200 mg twice daily can be used
darunavir AUC ↑ 15% without dose adjustments.
darunavir Cmin ↔
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476) stavudine (HOS-088080) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) efavirenz (HOS-087947) ritonavir (HOS-084521) abacavir (HOS-088077) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage f8ead3f953777de3c19f091bf055bc5528212e16095144f2b7b3940946af839d · Zeichen 6411–12375 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 91
HOS-116585 · Präparat HOS-094447
Medicinal products that affect darunavir exposure (cobicistat as pharmacoenhancer)
Darunavir and cobicistat are metabolised by CYP3A, and co-administration with CYP3A inducers
may therefore result in subtherapeutic plasma exposure to darunavir. Darunavir boosted with
cobicistat is more sensitive to CYP3A induction than ritonavir-boosted darunavir: co-administration of
darunavir/cobicistat with medicinal products that are strong inducers of CYP3A (e.g. St John’s Wort,
rifampicin, carbamazepine, phenobarbital, and phenytoin) is contraindicated (see section 4.3).
Co-administration of darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz,
etravirine, nevirapine, fluticasone, and bosentan) is not recommended (see interaction table below).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluticasone (HOS-108914) phenobarbital (HOS-085617) carbamazepine (HOS-085618) cobicistat (HOS-088111) etravirine (HOS-088088) efavirenz (HOS-087947) nevirapine (HOS-088064) bosentan (HOS-086291) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 499fe975cadb623876cff05939c4a88040eadfa5e659976989ecadcee7dec64a · Zeichen 1463–2226 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 94–95
HOS-116605 · Präparat HOS-094447
94
Etravirine etravirine AUC ↓ 37% PREZISTA co-administered with
100 mg twice daily etravirine Cmin ↓ 49% low dose ritonavir and etravirine
etravirine Cmax ↓ 32% 200 mg twice daily can be used
darunavir AUC ↑ 15% without dose adjustments.
darunavir Cmin ↔
darunavir Cmax ↔ Co-administration with
PREZISTA co-administered with
cobicistat is not recommended (see
section 4.4).
Nevirapine nevirapine AUC ↑ 27% PREZISTA co-administered with
200 mg twice daily nevirapine Cmin ↑ 47% low dose ritonavir and nevirapine
nevirapine Cmax ↑ 18% can be used without dose
#
darunavir: concentrations were adjustments.
consistent with historical data
(↑ nevirapine from CYP3A inhibition) Co-administration with
PREZISTA co-administered with
cobicistat is not recommended (see
section 4.4).
Rilpivirine rilpivirine AUC ↑ 130% Boosted PREZISTA and rilpivirine
150 mg once daily rilpivirine Cmin ↑ 178% can be used without dose
rilpivirine Cmax ↑ 79% adjustments.
darunavir AUC ↔
darunavir Cmin ↓ 11%
darunavir Cmax ↔
HIV Protease inhibitors (PIs) - without additional co-administration of low dose ritonavir†
Atazanavir atazanavir AUC ↔ PREZISTA co-administered with
300 mg once daily atazanavir Cmin ↑ 52% low dose ritonavir and atazanavir
atazanavir Cmax ↓ 11% can be used without dose
#
darunavir AUC ↔ adjustments.
#
darunavir Cmin ↔
# PREZISTA co-administered with
darunavir Cmax ↔
cobicistat should not be used in
combination with another
Atazanavir: comparison of
antiretroviral agent that requires
atazanavir/ritonavir 300/100 mg once
pharmacoenhancement by means
daily vs. atazanavir 300 mg once daily in
of co-administration with an
combination with darunavir/ritonavir
inhibitor of CYP3A4 (see section
400/100 mg twice daily.
4.5).
Darunavir: comparison of
darunavir/ritonavir 400/100 mg twice
daily vs. darunavir/ritonavir 400/100 mg
twice daily in combination with
atazanavir 300 mg once daily.
Indinavir indinavir AUC ↑ 23% When used in combination with
800 mg twice daily indinavir Cmin ↑ 125% PREZISTA co-administered with
indinavir Cmax ↔ low dose ritonavir, dose
#
darunavir AUC ↑ 24% adjustment of indinavir from
#
darunavir Cmin ↑ 44% 800 mg twice daily to 600 mg
# twice daily may be warranted in
darunavir Cmax ↑ 11%
case of intolerance.
Indinavir: comparison of
PREZISTA co-administered with
indinavir/ritonavir 800/100 mg twice
cobicistat should not be used in
daily vs. indinavir/darunavir/ritonavir
combination with another
800/400/100 mg twice daily.
antiretroviral agent that requires
Darunavir: comparison of
pharmacoenhancement by means
darunavir/ritonavir 400/100 mg twice
of co-administration with an
daily vs. darunavir/ritonavir 400/100 mg
inhibitor of CYP3A4 (see section
in combination with indinavir 800 mg
4.5).
twice daily.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) protease (HOS-085623) cobicistat (HOS-088111) etravirine (HOS-088088) rilpivirine (HOS-088090) nevirapine (HOS-088064) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 82dba6eed383a8de0a816a298d00d50916ec09c3124da8f7bdd64c11a3687248 · Zeichen 15880–22363 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-116820 · Präparat HOS-094481
11
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
In vitro the following May increase tacrolimus whole Monitor tacrolimus whole
substances have been shown blood trough concentrations and blood trough concentrations
to be potential inhibitors of increase the risk of serious adverse and reduce tacrolimus dose if
tacrolimus metabolism: reactions (e.g., neurotoxicity, QT needed [see section 4.2].
bromocriptine, cortisone, prolongation) [see section 4.4]. Monitor renal function, ECG
dapsone, ergotamine, for QT prolongation, and other
gestodene, lidocaine, side effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen
Strong CYP3A4 inducers: May decrease tacrolimus whole It is recommended that
rifampicin, phenytoin, blood trough concentrations and concomitant use should be
carbamazepine, apalutamide, increase the risk of rejection [see avoided. If unavoidable,
enzalutamide, mitotane, or section 4.4]. patients may require an
St. John’s wort (Hypericum Maximal effect on tacrolimus blood increase in tacrolimus dose.
perforatum) concentrations may be achieved 1-2 Changes in tacrolimus dose
weeks after co-administration. The should be individualized and
effect may remain 1-2 weeks after adjusted as needed based on
completion of the treatment. tacrolimus trough
concentrations, which should
be assessed at initiation,
monitored frequently
throughout (starting within the
first few days) and re-
evaluated on and after
completion of the CYP3A4
inducer. After use of the
CYP3A4 inducer has ended,
tacrolimus dose may need to
be adjusted gradually. Monitor
graft function closely.
Moderate CYP3A4 inducers: May decrease tacrolimus whole Monitor tacrolimus whole
metamizole, phenobarbital, blood trough concentrations and blood trough concentrations
isoniazid, rifabutin, increase the risk of rejection [see and increase tacrolimus dose if
efavirenz, etravirine, section 4.4]. needed [see section 4.2].
nevirapine; weak CYP3A4 Monitor graft function closely.
inducers: flucloxacillin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) phenobarbital (HOS-085617) lidocaine (HOS-108866) carbamazepine (HOS-085618) rifabutin (HOS-086262) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) etravirine (HOS-088088) mephenytoin (HOS-109801) mitotane (HOS-112479) bromocriptine (HOS-090620) efavirenz (HOS-087947) nilvadipine (HOS-116826) gestodene (HOS-116824) nevirapine (HOS-088064) ergotamine (HOS-086154) isoniazid (HOS-088590) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 9f68b7412442537a87ae5cc4a11a2083ae7ee1d4f84bacfd72b3336085546560 · Zeichen 8467–12012 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-118460 · Präparat HOS-094825
8
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Efavirenz 600 mg QD Maraviroc AUC12: ↓ 0.55 CELSENTRI dose should
(maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.49 be increased to 600 mg
Efavirenz concentrations not twice daily when
measured, no effect is expected. co-administered with
efavirenz in the absence of
a potent CYP3A4
inhibitor. For combination
with efavirenz + PI, see
separate recommendations
below.
Etravirine 200 mg BID Maraviroc AUC12: ↓ 0.47 Etravirine is only
(maraviroc 300 mg BID) Maraviroc Cmax: ↓ 0.40 approved for use with
boosted protease
Etravirine AUC12: ↔ 1.06 inhibitors. For
Etravirine Cmax: ↔ 1.05 combination with
Etravirine C12: ↔ 1.08 etravirine + PI, see below.
Nevirapine 200 mg BID Maraviroc AUC12: ↔ compared to Comparison to exposure
(maraviroc 300 mg Single historical controls in historical controls
Dose) Maraviroc Cmax: ↑ compared to suggests that
historical controls CELSENTRI 300 mg
Nevirapine concentrations not twice daily and nevirapine
measured, no effect is expected. can be co-administered
without dose adjustment.
Protease Inhibitors (PIs)
Atazanavir 400 mg QD Maraviroc AUC12 ↑ 3.57 CELSENTRI dose should
(maraviroc 300 mg BID) Maraviroc Cmax: ↑ 2.09 be decreased to 150 mg
Atazanavir concentrations not twice daily when
measured, no effect is expected. co-administered with a PI;
Atazanavir/ritonavir Maraviroc AUC12 ↑ 4.88 except in combination with
300 mg/100 mg QD Maraviroc Cmax: ↑ 2.67 tipranavir/ritonavir where
(maraviroc 300 mg BID) Atazanavir/ritonavir concentrations the CELSENTRI dose
not measured, no effect is expected. should be 300 mg BID.
Lopinavir/ritonavir Maraviroc AUC12 ↑ 3.95
400 mg/100 mg BID Maraviroc Cmax: ↑ 1.97
(maraviroc 300 mg BID) Lopinavir/ritonavir concentrations
not measured, no effect is expected.
Saquinavir/ritonavir Maraviroc AUC12 ↑ 9.77
1000 mg/100 mg BID Maraviroc Cmax: ↑ 4.78
(maraviroc 100 mg BID) Saquinavir/ritonavir concentrations
not measured, no effect is expected.
Darunavir/ritonavir Maraviroc AUC12 ↑ 4.05
600 mg/100 mg BID Maraviroc Cmax: ↑ 2.29
(maraviroc 150 mg BID) Darunavir/ritonavir concentrations
were consistent with historical data.
Nelfinavir Limited data are available for co-
administration with nelfinavir.
Nelfinavir is a potent CYP3A4
inhibitor and would be expected to
increase maraviroc concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) nelfinavir (HOS-084520) protease (HOS-085623) etravirine (HOS-088088) saquinavir (HOS-084522) darunavir (HOS-086181) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage ff4ede77b021b79f170216350386382bc99ed453e8d4f1e2c10da1c96acd8c4d · Zeichen 6618–10485 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-118466 · Präparat HOS-094825
10
Etravirine and Maraviroc AUC12: ↑ 3.10 CELSENTRI dose should
darunavir/ritonavir Maraviroc Cmax: ↑ 1.77 be decreased to 150 mg
(maraviroc 150 mg BID) twice daily when
Etravirine AUC12: ↔ 1.00 co-administered with
Etravirine Cmax: ↔ 1.08 etravirine and a PI.
Etravirine C12: ↓ 0.81
Concomitant use of
Darunavir AUC12: ↓ 0.86 CELSENTRI and
Darunavir Cmax: ↔ 0.96 fosamprenavir/ritonavir is
Darunavir C12: ↓ 0.77 not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): etravirine (HOS-088088) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage a57c8c01f9dcf834aa2f4b4cc59c3d274cf395ca1d07640063148f1c61905525 · Zeichen 13221–14057 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-118467 · Präparat HOS-094825
Ritonavir AUC12: ↔ 0.93
Ritonavir Cmax: ↔ 1.02
Ritonavir C12: ↓ 0.74
Etravirine and Not studied. Based on the extent of
lopinavir/ritonavir, inhibition by lopinavir/ritonavir,
saquinavir/ritonavir or saquinavir/ritonavir or
atazanavir/ritonavir atazanavir/ritonavir in the absence of
etravirine, an increased exposure is
expected.
ANTIBIOTICS
Sulphamethoxazole/ Maraviroc AUC12: ↔ 1.11 CELSENTRI 300 mg
Trimethoprim Maraviroc Cmax: ↔ 1.19 twice daily and
800 mg/160 mg BID Sulphamethoxazole/trimethoprim sulphamethoxazole/
(maraviroc 300 mg BID) concentrations not measured, no trimethoprim can be
effect expected. co-administered without
dose adjustment.
Rifampicin 600 mg QD Maraviroc AUC: ↓ 0.37 CELSENTRI dose should
(maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.34 be increased to 600 mg
Rifampicin concentrations not twice daily when
measured, no effect expected. co-administered with
rifampicin in the absence
of a potent CYP3A4
inhibitor. This dose
adjustment has not been
studied in HIV patients.
See also section 4.4.
Rifampicin + efavirenz Combination with two inducers has Concomitant use of
not been studied. There may be a risk CELSENTRI and
of suboptimal levels with risk of loss rifampicin + efavirenz is
of virologic response and resistance not recommended.
development.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) trimethoprim (HOS-085184) etravirine (HOS-088088) saquinavir (HOS-084522) efavirenz (HOS-087947) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 1af4c98082c3a7953761e56ffc31f5f4a9006530d26915e9825d9b7b7263f12b · Zeichen 14085–16301 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 35–36
HOS-118504 · Präparat HOS-094825
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
35
Efavirenz 600 mg QD Maraviroc AUC12: ↓ 0.55 CELSENTRI dose should be
(maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.49 increased to 600 mg twice
Efavirenz concentrations not daily when co-administered
measured, no effect is expected. with efavirenz in the absence
of a potent CYP3A4 inhibitor.
For combination with
efavirenz + PI, see separate
recommendations below.
Etravirine 200 mg BID Maraviroc AUC12: ↓ 0.47 Etravirine is only approved
(maraviroc 300 mg BID) Maraviroc Cmax: ↓ 0.40 for use with boosted protease
inhibitors. For combination
Etravirine AUC12: ↔ 1.06 with etravirine + PI, see
Etravirine Cmax: ↔ 1.05 below.
Etravirine C12: ↔ 1.08
Nevirapine 200 mg BID Maraviroc AUC12: ↔ compared to Comparison to exposure in
(maraviroc 300 mg Single historical controls historical controls suggests
Dose) Maraviroc Cmax: ↑ compared to that CELSENTRI 300 mg
historical controls twice daily and nevirapine
Nevirapine concentrations not can be co-administered
measured, no effect is expected. without dose adjustment.
Protease Inhibitors (PIs)
Atazanavir 400 mg QD Maraviroc AUC12 ↑ 3.57 CELSENTRI dose should be
(maraviroc 300 mg BID) Maraviroc Cmax: ↑ 2.09 decreased to 150 mg twice
Atazanavir concentrations not daily when co-administered
measured, no effect is expected. with a PI; except in
Atazanavir/ritonavir Maraviroc AUC12 ↑ 4.88 combination with
300 mg/100 mg QD Maraviroc Cmax: ↑ 2.67 tipranavir/ritonavir where the
(maraviroc 300 mg BID) Atazanavir/ritonavir concentrations CELSENTRI dose should be
not measured, no effect is expected. 300 mg BID.
Lopinavir/ritonavir Maraviroc AUC12 ↑ 3.95
400 mg/100 mg BID Maraviroc Cmax: ↑ 1.97
(maraviroc 300 mg BID) Lopinavir/ritonavir concentrations not
measured, no effect is expected.
Saquinavir/ritonavir Maraviroc AUC12 ↑ 9.77
1000 mg/100 mg BID Maraviroc Cmax: ↑ 4.78
(maraviroc 100 mg BID) Saquinavir/ritonavir concentrations
not measured, no effect is expected.
Darunavir/ritonavir Maraviroc AUC12 ↑ 4.05
600 mg/100 mg BID Maraviroc Cmax: ↑ 2.29
(maraviroc 150 mg BID) Darunavir/ritonavir concentrations
were consistent with historical data.
Nelfinavir Limited data are available for co-
administration with nelfinavir.
Nelfinavir is a potent CYP3A4
inhibitor and would be expected to
increase maraviroc concentrations.
Indinavir Limited data are available for co-
administration with indinavir.
Indinavir is a potent CYP3A4
inhibitor. Population PK analysis in
phase 3 studies suggests dose
reduction of maraviroc when
co-administered with indinavir gives
appropriate maraviroc exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) atazanavir (HOS-086180) nelfinavir (HOS-084520) protease (HOS-085623) etravirine (HOS-088088) saquinavir (HOS-084522) darunavir (HOS-086181) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 7650f006f70b016bab6056d849002bce692250e81f8df584dba8f3d456e3ce88 · Zeichen 6597–10790 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 37
HOS-118507 · Präparat HOS-094825
NNRTI + PI
Efavirenz 600 mg QD + Maraviroc AUC12: ↑ 2.53 CELSENTRI dose should be
lopinavir/ritonavir Maraviroc Cmax: ↑ 1.25 decreased to 150 mg twice
400mg/100 mg BID Efavirenz, lopinavir/ritonavir daily when co-administered
(maraviroc 300 mg BID) concentrations not measured, no with efavirenz and a PI
effect expected. (except tipranavir/ritonavir
Efavirenz 600 mg QD + Maraviroc AUC12: ↑ 5.00 where the dose should be 600
saquinavir/ritonavir Maraviroc Cmax: ↑ 2.26 mg twice daily).
1000 mg/100 mg BID Efavirenz, saquinavir/ritonavir Concomitant use of
(maraviroc 100 mg BID) concentrations not measured, no CELSENTRI and
effect expected. fosamprenavir/ritonavir is not
Efavirenz and Not studied. Based on the extent of recommended.
atazanavir/ritonavir or inhibition by atazanavir/ritonavir or
darunavir/ritonavir darunavir/ritonavir in the absence of
efavirenz, an increased exposure is
expected.
Etravirine and Maraviroc AUC12: ↑ 3.10 CELSENTRI dose should be
darunavir/ritonavir Maraviroc Cmax: ↑ 1.77 decreased to 150 mg twice
(maraviroc 150 mg BID) daily when co-administered
Etravirine AUC12: ↔ 1.00 with etravirine and a PI.
Etravirine Cmax: ↔ 1.08 Concomitant use of
Etravirine C12: ↓ 0.81 CELSENTRI and
fosamprenavir/ritonavir is not
Darunavir AUC12: ↓ 0.86 recommended.
Darunavir Cmax: ↔ 0.96
Darunavir C12: ↓ 0.77
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) etravirine (HOS-088088) saquinavir (HOS-084522) darunavir (HOS-086181) efavirenz (HOS-087947) fosamprenavir (HOS-086182) ritonavir (HOS-084521) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage cc48118abab80b247be7eabe93fc85e4af4bd16b91df9cd3fc2e334602646eb7 · Zeichen 11782–13823 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 37–38
HOS-118508 · Präparat HOS-094825
Ritonavir AUC12: ↔ 0.93
Ritonavir Cmax: ↔ 1.02
Ritonavir C12: ↓ 0.74
Etravirine and Not studied. Based on the extent of
lopinavir/ritonavir, inhibition by lopinavir/ritonavir,
saquinavir/ritonavir or saquinavir/ritonavir or
atazanavir/ritonavir atazanavir/ritonavir in the absence of
etravirine, an increased exposure is
expected.
ANTIBIOTICS
37
Sulphamethoxazole/ Maraviroc AUC12: ↔ 1.11 CELSENTRI 300 mg twice
Trimethoprim Maraviroc Cmax: ↔ 1.19 daily and sulphamethoxazole/
800 mg/160 mg BID Sulphamethoxazole/trimethoprim trimethoprim can be
(maraviroc 300 mg BID) concentrations not measured, no co-administered without dose
effect expected. adjustment.
Rifampicin 600 mg QD Maraviroc AUC: ↓ 0.37 CELSENTRI dose should be
(maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.34 increased to 600 mg twice
Rifampicin concentrations not daily when co-administered
measured, no effect expected. with rifampicin in the absence
of a potent CYP3A4 inhibitor.
This dose adjustment has not
been studied in HIV patients.
See also section 4.4.
Rifampicin + efavirenz Combination with two inducers has Concomitant use of
not been studied. There may be a risk CELSENTRI and rifampicin
of suboptimal levels with risk of loss + efavirenz is not
of virologic response and resistance recommended.
development.
Rifabutin + PI Not studied. Rifabutin is considered CELSENTRI dose should be
to be a weaker inducer than decreased to 150 mg twice
rifampicin. When combining rifabutin daily when co-administered
with protease inhibitors that are with rifabutin and a PI
potent inhibitors of CYP3A4 a net (except tipranavir/ritonavir
inhibitory effect on maraviroc is where the dose should be 300
expected. mg twice daily). See also
section 4.4.
Concomitant use of
CELSENTRI and
fosamprenavir/ritonavir is not
recommended.
Clarithromycin, Not studied, but both are potent CELSENTRI dose should be
Telithromycin CYP3A4 inhibitors and would be decreased to 150 mg twice
expected to increase maraviroc daily when co-administered
concentrations. with clarithromycin and
telithromycin.
ANTICONVULSANTS
Carbamezepine, Not studied, but these are potent CELSENTRI dose should be
Phenobarbital, CYP3A4 inducers and would be increased to 600 mg twice
Phenytoin expected to decrease maraviroc daily when co-administered
concentrations. with carbamazepine,
phenobarbital or phenytoin in
the absence of a potent
CYP3A4 inhibitor.
ANTIFUNGALS
Ketoconazole 400 mg QD Maraviroc AUCtau: ↑ 5.00 CELSENTRI dose should be
(maraviroc 100 mg BID) Maraviroc Cmax: ↑ 3.38 decreased to 150 mg twice
Ketoconazole concentrations not daily when co-administered
measured, no effect is expected. with ketoconazole.
Itraconazole Not studied. Itraconazole, is a potent CELSENTRI dose should be
CYP3A4 inhibitor and would be decreased to 150 mg twice
expected to increase the exposure of daily when co-administered
maraviroc. with itraconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) trimethoprim (HOS-085184) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) rifabutin (HOS-086262) etravirine (HOS-088088) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) efavirenz (HOS-087947) fosamprenavir (HOS-086182) ritonavir (HOS-084521) phenytoin (HOS-084531) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 1b627b7cd1e4efc3a8fc8f7680c5fda5526614bbd2d1f72d7ed1fca6f8314992 · Zeichen 13851–18833 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.